Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past
decade, have shown promising results in decreasing HPV infection and related diseases …

Human papillomavirus (HPV) is currently linked to almost 35,000 new cases of cancer in
women and men each year in the United States. Gardasil‐9 (Merck & Company), the only …

Summary Background The WHO Director-General has issued a call for action to eliminate
cervical cancer as a public health problem. To help inform global efforts, we modelled …

Background Single-dose human papillomavirus (HPV) vaccination, if efficacious, would be
tremendously advantageous, simplifying implementation and decreasing costs. Methods We …

Cervical cancer burden is high where prophylactic vaccination and screening coverage are
low. We demonstrated in a multicenter randomized, double-blind, controlled trial that single …

Video Abstract BACKGROUND AND OBJECTIVES The 9-valent human papillomavirus
(9vHPV) vaccine Phase III immunogenicity study in 9-to 15-year-old boys and girls was …

Background Given the accumulating evidence that one-dose vaccination could provide high
and sustained protection against human papillomavirus (HPV) infection and related …

Nicotinamide (NAM) is a water-soluble form of Vitamin B3 (niacin) and a precursor of
nicotinamide-adenine dinucleotide (NAD+) which regulates cellular energy metabolism …

With major advances in understanding the infectious etiology of cervical cancer, preventive
medicine has obtained highly promising new tools. Human papillomavirus (HPV) vaccines …

Background Oncogenic human papillomavirus (HPV) infections cause most cases of
cervical cancer. Here, we report long-term follow-up results for the Costa Rica Vaccine Trial …